- Source: ADH-1
ADH-1 (brand name Exherin) is a small, cyclic pentapeptide vascular-targeting drug. It was developed by Adherex Technologies.
ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell–cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.
In 2006, Adherex and NCI formed a clinical trial agreement stating that NCI will sponsor clinical trials of ADH-1 in a variety of cancer types. ADH-1 received orphan drug status from the FDA in 2008.
In a pilot study (phase I trial), ADH-1 intravenous pretreatment before chemotherapy in metastatic melanoma completely destroyed tumors in half of patients. It is being investigated in phase II trials for advanced extremity melanoma.
References
Kata Kunci Pencarian:
- Surah Ad-Duha
- Adh-Dhahhak bin Qais
- Muhammad bin Ismail al-Bukhari
- Ridwan
- Alkohol dehidrogenase
- Umar bin Hafidz
- Akuaporin 1
- Kelenjar endokrin
- Kleopatra
- Chavchay Syaifullah
- ADH-1
- Alcohol dehydrogenase
- ADH TV
- Syndrome of inappropriate antidiuretic hormone secretion
- Alcohol flush reaction
- Adh-Dhariyat
- Hyponatremia
- Al-Dhahabi
- Diabetes insipidus
- Atypical ductal hyperplasia
No More Posts Available.
No more pages to load.
